Anticoagulant News and Research

RSS
Study reveals overall success rate of AF ablation in Europe

Study reveals overall success rate of AF ablation in Europe

FDA accepts Regado Biosciences' IND application for REG2

FDA accepts Regado Biosciences' IND application for REG2

Ipsen’s phase III clinical trial evaluating Decapeptyl in patients with prostate cancer meets primary endpoints

Ipsen’s phase III clinical trial evaluating Decapeptyl in patients with prostate cancer meets primary endpoints

Findings raise hope for new oral anticoagulants to treat patients with atrial fibrillation

Findings raise hope for new oral anticoagulants to treat patients with atrial fibrillation

Aspirin prescribed more often for stroke prevention in AF despite of dangerous side effects

Aspirin prescribed more often for stroke prevention in AF despite of dangerous side effects

Alexion's Soliris gets FDA orphan drug designation for DGF prevention in renal transplant patients

Alexion's Soliris gets FDA orphan drug designation for DGF prevention in renal transplant patients

Study shows that anticoagulant medicine appears to protect patients against stroke

Study shows that anticoagulant medicine appears to protect patients against stroke

Daiichi Sankyo submits Marketing Authorization Application for edoxaban to EMA

Daiichi Sankyo submits Marketing Authorization Application for edoxaban to EMA

ESC presents results of pilot registry on management and treatment of AF in Europe

ESC presents results of pilot registry on management and treatment of AF in Europe

Daiichi Sankyo submits LIXIANA supplemental NDA for review in Japan

Daiichi Sankyo submits LIXIANA supplemental NDA for review in Japan

Late-breaking abstracts on treatment of blood cancers and bleeding disorders presented at ASH meeting

Late-breaking abstracts on treatment of blood cancers and bleeding disorders presented at ASH meeting

Daiichi Sankyo presents subgroup analysis of Hokusai-VTE study at ASH annual meeting

Daiichi Sankyo presents subgroup analysis of Hokusai-VTE study at ASH annual meeting

Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting

Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting

Alnylam presents new pre-clinical data with ALN-AT3 for treatment of hemophilia and RBD

Alnylam presents new pre-clinical data with ALN-AT3 for treatment of hemophilia and RBD

Genetics and cardiovascular drugs: an interview with Nancy Lurker, CEO of PDI and Paul Kinnon, CEO of Transgenomic, Inc.

Genetics and cardiovascular drugs: an interview with Nancy Lurker, CEO of PDI and Paul Kinnon, CEO of Transgenomic, Inc.

Natural compound coumarins exhibit anti-inflammatory as well as anticoagulant activities

Natural compound coumarins exhibit anti-inflammatory as well as anticoagulant activities

Patients at highest risk for suffering full-blown ischemic attack less likely to receive optimal care

Patients at highest risk for suffering full-blown ischemic attack less likely to receive optimal care

Once-daily edoxaban prevents stroke in patients with atrial fibrillation

Once-daily edoxaban prevents stroke in patients with atrial fibrillation

Treating traumatic brain-injured patients with anticoagulant decreases risk of dangerous clots

Treating traumatic brain-injured patients with anticoagulant decreases risk of dangerous clots

Cardiovascular Institute researchers to showcase 22 abstracts at upcoming AHA Scientific Sessions

Cardiovascular Institute researchers to showcase 22 abstracts at upcoming AHA Scientific Sessions

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.